Barbara L. Jones | Authors


Frontline Treatment Considerations in Non-Small Cell Lung Cancer

February 26, 2014

Although the current standard of care for advanced NSCLC remains platinum doublet chemotherapy, recent evidence suggests that most newly diagnosed patients may be candidates for targeted therapy as firstline treatment.

Model Emerges for Targeting Oncogenes in NSCLC

December 03, 2013

Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of NSCLC, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of ALK.

A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanoma

November 21, 2013

T-VEC, a novel oncolytic immunotherapy derived from the herpes simplex virus type 1, demonstrated a significant improvement in DRR, the primary endpoint in a pivotal phase III trial in patients with stage IIIB-IV melanoma.

MPDL3280A Induces Durable Responses in NSCLC, Other Cancers

November 21, 2013

MPDL3280A produced durable responses in studies in patients with forms of locally advanced/metastatic cancers, including smokers with NSCLC who customarily have poorer responses to cancer therapies than nonsmokers.